News Center

Press Releases

January 3, 2017 
Millendo Therapeutics to Present at J.P. Morgan Healthcare Conference

November 17, 2016 
Millendo Therapeutics Announces Appointment of Christopher J. Seiter as Chief Financial Officer

November 3, 2016 
Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting

November 2, 2016 
Millendo Therapeutics Announces Data Presentations at Society for Endocrinology British Endocrine Societies Conference

October 13, 2016 
Millendo Therapeutics Announces Appointment of Three Vice Presidents

August 16, 2016 
Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome

July 27, 2016 
Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome

June 23, 2016 
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board

June 8, 2016 
Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Congenital Adrenal Hyperplasia

June 1, 2016 
Millendo Therapeutics to Present at the Jefferies 2016 Healthcare Conference

April 14, 2016 
Millendo Therapeutics Expands Management Team with Addition of Two Vice Presidents

March 18, 2016 
Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016

February 2, 2016 
Millendo Therapeutics to Present at Four Upcoming Conferences

January 5, 2016 
Millendo Licenses Phase 2 Polycystic Ovary Syndrome (PCOS) Drug Candidate from AstraZeneca and Secures Series B Financing of $62 Million to Advance Pipeline of Endocrine Disorder Therapies

October 1, 2015 
Atterocor Appoints Jeffery M. Brinza as Senior Vice President, Administration and General Counsel

March 3, 2015 
Atterocor Announces Data Presentations at ENDO 2015

December 11, 2014
Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers

November 12, 2014
Atterocor Appoints Pharis Mohideen, M.D., as Chief Medical Officer

June 12, 2014
Atterocor Announces Data Presentations at ICE/ENDO 2014

December 18, 2013
Atterocor Appoints Leading Experts to Clinical Advisory Board

October 15, 2013
Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma

August 3, 2012
Atterocor Launches Innovative Company Focused on Accelerated Development of Treatment for Adrenal Cancer; Secures $16 Million Series A Financing